Reliance, Inc. Announces Amended and Restated $1.5 Billion Credit Facility
SCOTTSDALE, Ariz., Sept. 16, 2024 (GLOBE NEWSWIRE) — Reliance, Inc. (NYSE: RS) announced today that effective September 10, 2024, it […]
ThreeD Capital Inc. Announces Its Intention To Effect A Normal Course Issuer Bid
TORONTO, Sept. 16, 2024 (GLOBE NEWSWIRE) — ThreeD Capital Inc. (“ThreeD” or the “Company”) (CSE:IDK / OTCQX:IDKFF) a Canadian-based venture […]
Haleon Selects PubMatic as Supply Optimisation Partner to Enable More Effective, Sustainable Media Buying
LONDON, Sept. 16, 2024 (GLOBE NEWSWIRE) — PubMatic (NASDAQ:PUBM), an independent technology company delivering digital advertising’s supply chain of the […]
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
– Confirmed partial responses (PRs) doubled to four since ASCO GI in MSS CRC patients without liver and peritoneal metastases […]
MaxCyte Signs Strategic Platform License with Kamau Therapeutics to Accelerate the Development of Cell Therapies for Genetic Diseases
ROCKVILLE, Md. and SOUTH SAN FRANCISCO, Calif., Sept. 15, 2024 (GLOBE NEWSWIRE) — MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a […]
Vera Bradley Foundation for Breast Cancer Raises $1,601,830 for Breast Cancer Research
FORT WAYNE, Ind., Sept. 15, 2024 (GLOBE NEWSWIRE) — The Vera Bradley Foundation for Breast Cancer (the “Foundation”) today announced […]
Replimune Presents Primary Analysis Data from IGNYTE Clinical Trial of RP1 Combined with Nivolumab in Anti-PD1 Failed Melanoma at European Society for Medical Oncology (ESMO) Congress 2024
Data from the IGNYTE primary analysis shows clinically meaningful activity across all subgroups, including those who had received prior anti-PD1 […]
MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024
Encouraging antitumor activity demonstrated with vobra duo as measured by 6-month landmark rPFS rate and ORR Patients remained on vobra […]
23andMe Therapeutics Announces Positive In Vivo Results for 23ME-01473, a Dual-Mechanism ULBP6-Targeting Antibody Currently in a Phase 1 Trial
23ME-01473 inhibited tumor growth in a patient-derived xenograft mouse model of non-small cell lung cancer Elevated levels of soluble and […]
23andMe Therapeutics Announces Phase 2 Results for Two Additional Cancer Cohorts and Correlative Biomarker Data from 23ME-00610 Study
23ME-00610 monotherapy demonstrates preliminary evidence of clinical benefit in clear-cell renal-cell carcinoma, with one confirmed partial response Higher tumor expression […]
